Bay City Capital
Venture capitalSan Rafael · Seed–Late Stage · 8 people tracked
Also known as BAY CITY CAPITAL LLC
Investment thesis
Bay City Capital is a life sciences investment firm that invests across a diversified strategy from seed stage to public companies, concentrating largely on the development of breakthrough therapeutics. In this initiative it partnered with Takeda, Deerfield Management, and three leading New York research institutions (Memorial Sloan Kettering, The Rockefeller University, and Weill Cornell Medicine) to launch Bridge Medicines, a drug discovery company that funds and professionally manages early-stage academic projects from proof-of-concept through IND filing and clinical development.
Source: firm website, verified Aug 11, 2026.
Team · 8 people
from the firm's website & public directories
What they invest in
from 22 of 82 portfolio companiesBiotech ×17Healthtech ×9Medical Devices ×4Digital Health ×2Consumer ×1Deep Tech ×1New Materials ×1Semiconductors ×1
HQs:United States×20Switzerland×2
Investments · 82 tracked
founders shown can be your intro pathBy year:2025 · 12019 · 12017 · 22016 · 22015 · 28 dated
Advancing potentially best-in-class therapeutics for myeloproliferative neoplasms.
Copenhagen, US
Board seatCarl Goldfischer· per SEC Form D · $285M raise · filed Nov 2025
BiotechCambridge, US
Sara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)Robert Hopfner(Director)Mette Kirstine Agger(Director)James G. McArthur(Executive Officer, Director)
Board seatCarl Goldfischer· per SEC Form D
BiotechLouisville, US
Hoyoung Huh(Director, Executive Officer)Sankaram Mantripragada(Executive Officer)Nevan Charles Elam(Executive Officer, Director)Barry Sherman(Director)Morgan Lynn Fields(Executive Officer)
Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an investigational drug candidate for treating pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
BiotechDigital HealthMedical DevicesSan Diego, US
Bryan Giraudo(Executive Officer)Faheem Hasnain(Executive Officer, Director)Russell Cox(Director)Renee Gala(Director)Laura Carter, Ph.D.(Executive Officer)Christian Waage(Executive Officer)
BiotechSouth Plainfield, US
Dawn Svoronos(Director)Stuart W. Peltz(Executive Officer, Director)David P. Southwell(Director)Allan S. Jacobson(Director)Mark E. Boulding(Executive Officer)Christine Utter(Executive Officer)
Twist Bioscience develops a silicon-based synthetic DNA manufacturing platform that produces high-quality DNA, genes, and NGS reagents for customers in medicine, agriculture, and industrial chemicals.
BiotechDeep TechSemiconductorsSouth San Francisco, US
Emily Marine Leproust(Executive Officer, Director, Promoter)William Charles Banyai(Executive Officer, Director, Promoter)Bill James Peck(Executive Officer, Promoter)Rob Chess(Director)
BoardKeith Crandell(Director)Paul Conley(Director)
Xilio (Xilio Therapeutics) is a clinical-stage biotechnology company developing tumor-selective immunotherapies, including checkpoint inhibitors, T cell engagers and related molecules, for the treatment of cancer.
BiotechHealthtechWaltham, US
Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)Rachel Humphrey(Director)Daniel Lynch(Director)Michael Ross(Director)
HealthtechSt Paul, US
Gary D Blackford(Director)Dan W Gladney(Executive Officer, Director)Scott P Youngstrom(Executive Officer)Rajesh Nihalani(Executive Officer)Peter M DeLange(Executive Officer)Bobby I Griffin(Director)
Board seatCarl Goldfischer· per SEC Form D
HealthtechSan Diego, US
Robert Williamson(Executive Officer, Director, Promoter)John Hutchinson(Executive Officer)Vanessa Jacoby(Executive Officer)Rupert Vessey(Director)
Board seatCarl Goldfischer· per SEC Form D · $3M raise · filed Sep 2016
BiotechSacramento, US
Woodrow A. Myers, Jr.(Director)Vic Schmitt(Director)Chuck Novak(Vice President and Chief Financial Officer of the Issuer)George Barry(Co-Founder of Issuer)Philip H. Coelho(Chief Technology Officer and Co-Founder of Issuer)William Gerber(Chief Executive Officer and President of Issuer)
Board seatCarl Goldfischer· per SEC Form D
BiotechSouth San Francisco, US
Cameron Wheeler(Director)Elaine Jones(Director)Wendye Robbins(Executive Officer, Director)William Slattery(Director)James Scopa(Director)
BoardLuke Evnin(Director)
Gilead Sciences is a biopharmaceutical company that develops medicines across virology, oncology, and inflammation, with more than 25 medicines offered globally and a clinical pipeline spanning these three therapeutic areas.
BiotechHealthtechNewark, US
Harold Van Wart, Ph. D.(Executive Officer, Director)Carl Goldfischer, M.D.(Director)Pol Boudes(Executive Officer)Kurt von Emster(Director)Hari Kumar, Ph.D.(Director)Charles A. McWherter, Ph. D.(Executive Officer)
HealthtechMenlo Park, US
LUIS PENA(Executive Officer)CHRISTOPHER GRIFFITH(Executive Officer)KATHLEEN SEBELIUS(Director)DAVID E. COHEN(Director)THOMAS G. WIGGANS(Executive Officer, Director)EUGENE A. BAUER(Executive Officer, Director)
Biopharmaceutical company developing innovative therapies for chronic diseases using proprietary drug delivery systems.
BiotechBoston, US
James Ahlers(Executive Officer)Irwin Scher(Director)John Yee(Executive Officer)Sunita Zalani(Executive Officer)Raymond T. Keane(Executive Officer)Emad Rizk(Director)
BiotechWatham, US
Joseph Landstra(Director)Kenneth Kornman(Executive Officer, Director)Roger Colman(Director)Dayton Misfeldt(Director)Stephen DiPalma(Executive Officer)James Weaver(Director)
Iterum Therapeutics develops anti-infective compounds to treat infections caused by multi-drug resistant pathogens.
BiotechDigital HealthHealthtechMedical DevicesDublin, US
Brenton K. Ahrens(Director)Michael W. Dunne(Executive Officer, Promoter)Ronald M. Hunt(Director)Mark Chin(Director)Corey N. Fishman(Executive Officer, Director, Promoter)Robert Hopfner(Director)
KBP is a biotechnology research and development organization that discovers and develops new therapies for unmet medical needs.
Biotech
BiotechSouth San Francisco, US
John F. Fowler(Executive Officer, Director)Dr. Gerald Chan(Director)Dr. Jean-Pierre Sommadossi(Director)Christopher J. Kirk(Executive Officer, Director)
QUILLIVANT XR is a prescription medication containing methylphenidate, indicated for ADHD treatment.
Medical DevicesNew Jersey, US
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 8
IPOs and acquisitions across the tracked portfolioDamora TherapeuticsNASDAQ: DMRAImaraNASDAQ: ELVNAntriaBioNASDAQ: RZLTGossamer BioNASDAQ: GOSSNextCureNASDAQ: NXTCPtc TherapeuticsNASDAQ: PTCTTwist BioscienceNASDAQ: TWSTXilio TherapeuticsNASDAQ: XLO
Portfolio news
latest coverage across their companiesFrequently asked questions
- What stage does Bay City Capital invest at?
- Bay City Capital invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Bay City Capital's typical check size?
- Bay City Capital typically writes checks of $5M – $10M.
- What sectors does Bay City Capital focus on?
- Bay City Capital focuses on Biotech, Digital Health, Enterprise Software, Healthtech, Medical Devices.
- Where is Bay City Capital located?
- Bay City Capital is headquartered in San Rafael, US.
Similar investors
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.
SpringRock Ventures is a Seattle-based venture firm investing in the convergence of healthcare and information technology, backing companies across digital health, medical devices, oral health, healthcare SaaS and related innovation.
OUP (Osage University Partners) is a venture capital firm that backs startups spinning out of leading research labs and universities, partnering with founders, researchers, and academic institutions.